Effect of recombinant human erythropoietin in peri-operative phase of cardiac surgery

Abstract

Objective: To study the effect of recombinant human erythropoietin (rHuEPO) in peri-operative phase of cardiac surgery. Methods: Sixty-four patients with cardiac surgery by extracorporeal circulation were divided into to experiment group and control group. Patients of experiment group accepted rHuEPO 10000U per injection alt dieb by subcutaneous injection from 7 days before surgery to 7 days after surgery, simultaneously took orally ferrous gluconate 400 mg tid. Therapy of control group identified with experiment group except rHuEPO therapy. Results: (1) Compared with control group the reticulocyte (RC), ferrohemogrobin (Hb), hemotocrit (Hct) level significantly increased (P0. 05 all) on 7th, 14th day after surgery in experiment group, those indexes reached a high tide or normal levels on 14th day; (2) The difference of ALT、BUN、Cr、PT、Fg etc levels between 2 groups was no significant (P0. 05 all); (3) Compared with control group the volume of blood transfusion significantly decreased (450±180ml vs 760±330ml,P0. 05) but volume of blood loss was no significant difference(P0. 05). Conclusion:The rHuEPO can facilitate generation of red cell and recovery of anemia after surgery; Simultaneously decrease volume of blood transfusion.

Ähnliche Arbeiten